Evidence map›Paper›PMID 40446057›Full record

ArticlePloS one2025

Preoperative kidney tumor risk estimation with AI: From logistic regression to transformer.

Vesna Barros, Nour Abdallah, Michal Ozery-Flato, Avihu Dekel, Moshiko Raboh, Nicholas Heller, Simona Rabinovici-Cohen, Alex Golts, Amilcare Gentili, Daniel Lang and 10 more

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Vesna BarrosIBM Research Israel, Haifa, Israel.ORCID 0000-0002-3057-8140
Nour AbdallahGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Michal Ozery-FlatoIBM Research Israel, Haifa, Israel.ORCID 0000-0002-8223-7989
Avihu DekelIBM Research Israel, Haifa, Israel.
Moshiko RabohIBM Research Israel, Haifa, Israel.
Nicholas HellerUniversity of Minnesota, Minneapolis, Minnesota, United States of America.
Simona Rabinovici-CohenIBM Research Israel, Haifa, Israel.
Alex GoltsIBM Research Israel, Haifa, Israel.
Amilcare GentiliSan Diego VA Health Care System, San Diego, California, United States of America.
Daniel LangInstitute of Radiation Medicine, Helmholtz Munich, Munich, Germany.
Suman ChaudharyTaiyuan University of Technology, Taiyuan, China.
Varsha SatishIndian Institute of Technology Bombay, Bombay, India.
Resha TejpaulUniversity of Minnesota, Minneapolis, Minnesota, United States of America.ORCID 0000-0003-4303-2160
Ivan EggelUniversity of Applied Sciences Western Switzerland (HES-SO), Sierre, Switzerland.
Itai GuezIBM Research Israel, Haifa, Israel.
Ella BarkanIBM Research Israel, Haifa, Israel.
Henning MüllerUniversity of Applied Sciences Western Switzerland (HES-SO), Sierre, Switzerland.
Efrat HexterIBM Research Israel, Haifa, Israel.
Michal Rosen-ZviIBM Research Israel, Haifa, Israel.ORCID 0000-0001-7616-9724
Christopher WeightGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We consider the problem of renal mass risk classification to support doctors in adjuvant treatment decisions following nephrectomy. Recommendation of adjuvant therapy based on the mass appearance poses two major challenges: first, morphologic patterns may sometimes overlap across subtypes of varying risks. Second, interobserver variability is large. These complexities encourage the use of computational models as accurate noninvasive tools to find relevant relationships between individual perioperative renal mass characteristics and patient risk. In addition, recent evidence highlights the importance of clinical context as a promising direction to inform treatment decisions post-nephrectomy. In this work, we aim to identify relevant clinical markers that can be predictive of renal cancer prognosis. As a starting point, we perform a clinical feature ablation study by training a logistic regression baseline model to predict renal cancer patients' eligibility for adjuvant therapy. The training dataset consisted of medical records of 300 individuals with renal tumors who underwent partial or radical nephrectomy between 2011 and 2020. In addition, we evaluate the same task using a transformer-based model pretrained on a much larger dataset of over 300,000 clinical records of individuals from the UK Biobank. Our findings demonstrate the pretrained model's efficacy in knowledge transfer across different populations, with radiographic data from preoperative cross-sectional imaging playing an important role in informing renal risk and treatment decisions.

Indexed as

Artificial IntelligenceKidney NeoplasmsAgedFemaleHumansLogistic ModelsMaleMiddle AgedNephrectomyPreoperative PeriodPrognosisRisk Assessment

Identifiers

PMID40446057
PMCPMC12124753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.